Harrison, LH, Trotter, CL, Ramsay, ME. Global epidemiology of meningococcal disease. Vaccine
2009; 27 (Suppl. 2): B51–B63.
Sáfadi, MA, et al.
The epidemiology of meningococcal disease in Latin America 1945–2010: an unpredictable and changing landscape. Epidemiology and Infection
2012; 9: 1–12.
Abad, R, et al.
Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region. Journal of Infection
2009; 59: 104–114.
Bröker, M, et al.
Increase of meningococcal serogroup Y cases in Europe: a reason for concern?
Human Vaccines and Immunotherapeutics
2012; 8: 685–688.
Caugant, DA, et al. (2012). Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012; 7: e46 019.
Mayer, LW, et al.
Outbreak of W meningococcal disease in 2000: not emergence of a new W strain but clonal expansion within the electrophoretic type-37 complex. Journal of Infectious Diseases
2002; 185: 1596–1605.
Griffiss, JM, Brandt, BL. Disease due to serogroup W Neisseria meningitidis
1979; 64: 218–221.
Kwara, A, et al.
Meningitis caused by a serogroup W clone of the ET37 complex of Neisseria meningitidis in West Africa. Tropical Medicine and International Health
1998; 3: 742–746.
Popovic, T, et al.
Neisseria meningitidis serogroup W isolates associated with the ET37 complex. Emerging Infectious Diseases
2000; 6: 428–429.
Hahné, SJ, et al.
W meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet
2002; 359: 582–583.
Taha, MK, et al.
Continuing diversification of Neisseria meningitidis W as a primary cause of meningococcal disease after emergence of the serogroup in 2000. Journal of Clinical Microbiology
2004; 42: 4158–4163.
Taha, MK, et al.
Neisseria meningitidis serogroups W and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. Journal of Clinical Microbiology
2002; 40: 1083–1084.
Koumaré, B, et al.
The first large epidemic of meningococcal disease caused by serogroup W, Burkina Faso, 2002. Vaccine
2007; 25 (Suppl. 1), A37–41.
MacLennan, JM, et al.
Carriage of serogroup W, ET37 meningococci in the Gambia: implications for immunisation policy. Lancet
2000; 356: 1078.
Kristiansen, PA, et al.
Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine. BMC Infectious Diseases
2013; 13: 363.
Wilder, Smith A, et al.
Persistence of W Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts. Emerging Infectious Diseases
2003; 9: 123–126.
Nicolas, P, et al.
Pharyngeal carriage of serogroup W Neisseria meningitidis in Hajjees and their family contacts in Morocco, Oman and Sudan. APMIS
2005; 113: 182–186.
Ceyhan, M, et al.
Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajj pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine. Clinical and Vaccine Immunology
2013; 20: 66–68.
Wilder-Smith, A, Chow, A, Goh, KT. Emergence and disappearance of W meningococcal disease. Epidemiology & Infection
2009; 138: 976–978.
Parent du Châtelet, I, Barboza, P, Taha, MK. W invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. Eurosurveillance
2012; 17: pii=20181.
Collard, JM, et al.
Increase in Neisseria meningitidis serogroup W, Niger, 2010. Emerging Infectious Diseases
2010; 16: 1496–1498.
Frasch, CE, Preziosi, MP, LaForce, FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac™. Human Vaccines and Immunotherapeutics
2012; 8: 715–724.
Djingareya, MH, et al.
Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine
2012; 30 (Suppl. 2): B40–B45.
Daugla, DM, et al.
Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet. Published online
Kristiansen, PA, et al.
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clinical Infectious Diseases
2013; 56: 354–363.
von Gottberg, A.
. Communicable Diseases Surveillance Bulletin
2012; 10: 60–63.
von Gottberg, A, et al.
Emergence of endemic serogroup W meningococcal disease associated with a high mortality rate in South Africa. Clinical Infectious Diseases
2008; 46: 377–386.
High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W:P1·5,2:ST11 clone in Southern Brazil. Journal of Infection
2008; 57: 324–331.
Barroso, DE, Rebelo, MC. Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W in the Rio de Janeiro region, Brazil. Memórias do Instituto Oswaldo Cruz
2007; 102: 773–775.
López, EL, Debbag, R. Meningococcal disease: always present. Serogroup changes in the Southern Cone. Revista Chilena de Infectología
2012; 29: 587–594.
Lemos, AP, et al.
Phenotypic and molecular characterization of invasive serogroup W Neisseria meningitidis strains from 1990 to 2005 in Brazil. Journal of Infection
2009; 60: 209–217.
Ferreira, E, et al.
Neisseria meningitidis serogroup W in Portugal – presence of the ST11/ET37 clonal complex. Pathologie Biologie
2007; 56: 94.
Ibarz-Pavón, AB, et al.
Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006–2010. PLoS One
2012; 7: e 44 102.
Efron, AM, et al.
W invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. Journal of Clinical Microbiology
2009; 47: 1979–1980.
Sorhouet-Pereira, C, et al.
Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010. PLoS One
2013; 8: e 58 065.
Barra, GN, et al.
Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010–2011. PLoS One
2013; 8: e 66 006.
Cohn, AC, Harrison, LH. Meningococcal vaccines: current issues and future strategies. Drugs
2013; 73: 1147–1155.
Taha, MK, et al.
Serogroup W meningococcal disease in Hajj pilgrims. Lancet
2000; 356: 2159.
Taha, MK, et al.
Travel-related Neisseria meningitidis serogroup W135 infection, France. Emerging Infectious Diseases
2013; 19: 1030–1032.
Doyle, TJ, et al.
Cluster of serogroup W135 meningococci, southeastern Florida, 2008–2009. Emerging Infectious Diseases
2010; 16: 113–115.
Jones, DM, Sutcliffe, EM. Group A meningococcal disease in England associated with the Hajj. Journal of Infection
1990; 21: 21–25.
Al-Gahtani, YM, et al.
Epidemiological investigation of an outbreak of meningococcal meningitis in Makkah (Mecca), Saudi-Arabia, 1992. Epidemiology & Infection
1995; 115: 399–409.
Wang, JF, et al.
Antigenic and epidemiologic properties of the ET37 complex of Neisseria meningitidis
. Journal of Infectious Diseases
1993; 167: 1320–1329.
Castilla, J, et al.
B:2a:P1·5 meningococcal strains likely arisen from capsular switching event still spreading in Spain. Journal of Clinical Microbiology
2009; 47: 463–465.
Zhou, H, et al.
Spread of Neisseria meningitidis serogroup W clone, China. Emerging Infectious Diseases
2013; 19: 1496–1469.